The Patent Finder

Xigen Inflammation Ltd.

Also on record
Records under this name other than the patents Xigen Inflammation Ltd. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 6 patents it holds.

Back to Xigen Inflammation Ltd.

PatentTitleStatus Expires Confidence
US 9,290,538Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway
Term ended
Term ended Sep 12, 2026 · High confidence
Term endedTerm ended Sep 12, 2026High confidence
US 10,023,615Efficient Transport into White Blood Cells
Lapsed on the fee record
Ended Jul 17, 2026 · High confidence
Lapsed on the fee recordEnded Jul 17, 2026High confidence
US 8,748,395Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway
Formerly held
Lapsed on the fee record
Ended Jun 10, 2026 · High confidence
Lapsed on the fee recordEnded Jun 10, 2026High confidence
US 11,331,364Use for JNK inhibitor molecules for treatment of various diseases
Lapsed on the fee record
Ended May 17, 2026 · From the USPTO record
Lapsed on the fee recordEnded May 17, 2026From the USPTO record
US 8,080,517Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway
Term ended
Term ended Sep 12, 2025 · High confidence
Term endedTerm ended Sep 12, 2025High confidence
US 9,624,267JNK inhibitor molecules
Lapsed on the fee record
Ended Apr 18, 2025 · From the USPTO record
Lapsed on the fee recordEnded Apr 18, 2025From the USPTO record
US 10,967,038Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
Lapsed on the fee record
Ended Apr 6, 2025 · From the USPTO record
Lapsed on the fee recordEnded Apr 6, 2025From the USPTO record
US 9,610,330Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases
Lapsed on the fee record
Ended Apr 4, 2025 · From the USPTO record
Lapsed on the fee recordEnded Apr 4, 2025From the USPTO record
US 8,183,339Cell-permeable peptide inhibitors of the JNK signal transduction pathway
Lapsed on the fee record
Ended May 22, 2024 · From the USPTO record
Lapsed on the fee recordEnded May 22, 2024From the USPTO record
US 10,596,223JNK inhibitor molecules for treatment of various diseases
Lapsed on the fee record
Ended Mar 24, 2024 · From the USPTO record
Lapsed on the fee recordEnded Mar 24, 2024From the USPTO record
10 of 13 patents shown.
Pro members see all 13.
Pro members: see all 13 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited